CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
体成分与营养状态同 CAR-T 细胞疗效的关联
英文原题：Linking Body Composition and Nutritional Status with CAR T-cell Efficacy.
查看英文原题
Linking Body Composition and Nutritional Status with CAR T-cell Efficacy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肥胖及其伴随的病理生理改变长期以来被认为可促进癌症发生并调节抗肿瘤免疫反应，但其对细胞免疫治疗结局的影响知之甚少。在本期中，Rejeski及其同事报告，包括身体成分和营养状态在内的宿主内在因素可能预测复发淋巴瘤患者接受CAR-T 细胞治疗后的反应。这些数据凸显了这些因素对治疗结局的临床相关性，并有望推动针对此类患者进行预康复和营养优化的干预性研究。参见Rejeski等人的相关文章，第707页(1)。
展开英文摘要原文
Obesity and its attendant pathophysiological alterations have long been implicated in promoting cancer development and in the modulation of antitumor immunologic responses, but little is known about their impact on outcomes after cellular immunotherapy.
In this issue, Rejeski and colleagues report that intrinsic host factors including body composition and nutritional status may predict response after chimeric antigen receptor T-cell therapy in patients with relapsed lymphomas. These data highlight the clinical relevance of these factors on treatment outcomes and will hopefully motivate interventional studies of prehabilitation and nutritional optimization in these patients. See related article by Rejeski et al. , p. 707 (1).
论文信息
- 作者
- Nawas MT、Scordo M
- 第一作者单位
- Hematopoietic Cellular Therapy Program, Section of Hematology and Oncology, Department of Medicine, The University of Chicago Medical Center.United States
- 通讯作者单位
- Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Assistant Professor, Department of Medicine, Weill Cornell Medical College.
- 文献类型
- 社论 · 评论
- 期刊
- Cancer immunology research2023 Jun 2
- 原文标识
- PubMed 37264818 · DOI 10.1158/2326-6066.CIR-23-0313